

Pediatric Pancreas Transplant Recipient Registration Worksheet

FORM APPROVED: O.M.B. NO. 0915-0157 Expiration Date: 08/31/2023

Note: These worksheets are provided to function as a guide to what data will be required in the online TIEDI® application. Currently in the worksheet, a red asterisk is displayed by fields that are required, independent of what other data may be provided. Based on data provided through the online TIEDI® application, additional fields that are dependent on responses provided in these required fields may become required as well. However, since those fields are not required in every case, they are not marked with a red asterisk.

| Recipient Information | |
|--|---|
| Name: | DOB: |
| SSN: | Gender: |
| HIC: | Tx Date: |
| State of Permanent Residence: * | <input type="text"/> |
| Permanent Zip: * | <input type="text"/> - <input type="text"/> |

| Provider Information | |
|--------------------------|----------------------|
| Recipient Center: | |
| Surgeon Name: * | <input type="text"/> |
| NPI#: * | <input type="text"/> |

| Donor Information | |
|-------------------------|--|
| UNOS Donor ID #: | |
| Recovering OPO: | |
| Donor Type: | |

| Patient Status | |
|---|--|
| Primary Diagnosis: * | <input type="text"/> |
| Specify: | <input type="text"/> |
| Date: Last Seen, Retransplanted or Death * | <input type="text"/> |
| Patient Status: * | <input type="radio"/> LIVING <input type="radio"/> DEAD <input type="radio"/> RETRANSPLANTED |
| Primary Cause of Death: | <input type="text"/> |
| Specify: | <input type="text"/> |
| Contributory Cause of Death: | <input type="text"/> |
| Specify: | <input type="text"/> |
| Contributory Cause of Death: | <input type="text"/> |
| Specify: | <input type="text"/> |
| Transplant Hospitalization: | |
| Date of Admission to Tx Center: * | <input type="text"/> |
| Date of Discharge from Tx Center: | <input type="text"/> |

| Clinical Information : PRETRANSPLANT | |
|--------------------------------------|--|
| Functional Status: * | <input type="text"/> |
| Cognitive Development: * | <input type="radio"/> Definite Cognitive delay/impairment <input type="radio"/> Probable Cognitive delay/impairment <input type="radio"/> Questionable Cognitive delay/impairment <input type="radio"/> No Cognitive delay/impairment <input type="radio"/> Not Assessed |

Motor Development: *

Probable Motor delay/impairment
 Questionable Motor delay/impairment
 No Motor delay/impairment
 Not Assessed

Academic Progress: *

Within One Grade Level of Peers
 Delayed Grade Level
 Special Education
 Not Applicable, too young for school/ High School graduate or GED
 Status Unknown

Academic Activity Level: *

Full academic load
 Reduced academic load
 Unable to participate in academics due to disease or condition
 Unable to participate regularly due to dialysis
 Not Applicable, too young for school/ High School graduate or GED
 Status Unknown

Source of Payment:

Primary: *

Specify:

Date of Measurement:

Height: * ft. in. cm **ST=**

Weight: * lbs kg **ST=**

BMI: kg/m²

Previous Transplants:

| Previous Transplant Organ | Previous Transplant Date | Previous Transplant Graft Fail Date |
|---------------------------|--------------------------|-------------------------------------|
| | | |

The three most recent transplants are listed here. Please contact the UNet Help Desk to confirm more than three previous transplants by calling 800-978-4334 or by emailing unethelpdesk@unos.org.

Pretransplant Dialysis: * YES NO UNK

If Yes, Date of Most Recent Initiation of Chronic Maintenance Dialysis: **ST=**

Average Daily Insulin Units: * units/kg/day **ST=**

Serum Creatinine at Time of Tx: * mg/dl **ST=**

Viral Detection:

HIV Serostatus: *

Positive
 Negative
 Not Done
 UNK/ Cannot Disclose

CMV Status: *

Positive
 Negative
 Not Done
 UNK/ Cannot Disclose

HBV Surface Antibody Total: *

Positive
 Negative
 Not Done
 UNK/ Cannot Disclose

Candidate Name: DOB:

| | |
|-----------------------|---|
| HBV Core Antibody:* | <input type="radio"/> Negative <input type="radio"/> Not Done <input type="radio"/> UNK/Cannot Disclose <input type="radio"/> Positive |
| HBV Surface Antigen:* | <input type="radio"/> Negative <input type="radio"/> Not Done <input type="radio"/> UNK/Cannot Disclose <input type="radio"/> Positive |
| HCV Serostatus:* | <input type="radio"/> Negative <input type="radio"/> Not Done <input type="radio"/> UNK/Cannot Disclose <input type="radio"/> Positive |
| EBV Serostatus:* | <input type="radio"/> Negative <input type="radio"/> Not Done <input type="radio"/> UNK/Cannot Disclose <input type="radio"/> Positive |
| NAT Results: | |
| HIV NAT:* | <input type="radio"/> Positive <input type="radio"/> Negative <input type="radio"/> Not Done <input type="radio"/> UNK/Cannot Disclose |
| HBV NAT:* | <input type="radio"/> Positive <input type="radio"/> Negative <input type="radio"/> Not Done <input type="radio"/> UNK/Cannot Disclose |
| HCV NAT:* | <input type="radio"/> Positive <input type="radio"/> Negative <input type="radio"/> Not Done <input type="radio"/> UNK/Cannot Disclose |

Malignancies between listing and transplant:* YES NO UNK

This question is NOT applicable for patients receiving living donor transplants who were never on the waiting list.

| | |
|-----------------------|---|
| If yes, specify type: | <input type="checkbox"/> Skin Melanoma |
| | <input type="checkbox"/> Skin Non-Melanoma |
| | <input type="checkbox"/> CNS Tumor |
| | <input type="checkbox"/> Genitourinary |
| | <input type="checkbox"/> Breast |
| | <input type="checkbox"/> Thyroid |
| | <input type="checkbox"/> Tongue/Throat/Larynx |
| | <input type="checkbox"/> Lung |
| | <input type="checkbox"/> Leukemia/Lymphoma |
| | <input type="checkbox"/> Liver |

Specify:

| |
|---|
| Clinical Information : TRANSPLANT PROCEDURE |
| Multiple Organ Recipient |
| Were extra vessels used in the transplant procedure: |

Surgical Information:

- Graft Placement:** * INTRA-PERITONEAL
 RETRO-PERITONEAL
 PARTIAL INTRA/RETRO-PERITONEAL
 PANCREAS ALONE
 CLUSTER
- Operative Technique:** * MULTI-ORGAN NON-CLUSTER
 PANCREAS AFTER KIDNEY
 PANCREAS WITH KIDNEY DIFFERENT DONOR
 ENTERIC W/ROUX-EN-Y
 ENTERIC W/O ROUX-EN-Y
 CYSTOSTOMY
- Duct Management:** * DUCT INJECTION IMMEDIATE
 DUCT INJECTION DELAYED
 OTHER SPECIFY
- Specify:
- Venous Vascular Management:** * SYSTEMIC SYSTEM (ILIAC:CAVA)
 PORTAL SYSTEM (PORTAL OR TRIBUTARIES)
 NA/Multi-organ cluster
 CELIAC WITH PANCREAS
 Y-GRAFT TO SPA & SMA
 SPA TO SMA DIRECT
- Arterial Reconstruction:** * SPA TO SMA WITH INTERPOSITION
 SPA ALONE
 OTHER SPECIFY
- Specify:
- Venous Extension Graft:** * YES NO

Preservation Information:

Total Pancreas Preservation Time (include Cold, Warm, Anastomotic time): * hrs ST=

Clinical Information : POST TRANSPLANT

Pancreas Graft Status: * Functioning Failed

If death is indicated for the recipient, report graft status up until the instance of death.

Candidate Name: DOB:

Patient using either oral medication or diet for blood sugar control:*

YES NO UNK

Patient on oral medication to control blood sugar?*

YES NO UNK

Date of medications resumed:*

ST=

Patient using diet to control blood sugar:*

YES NO UNK

Patient on insulin?*

YES NO UNK

Date insulin resumed:*

ST=

Average total insulin dosage per day:*

units/kg/day

ST=

Insulin duration of use:*

days

ST=

C-peptide value:

ng/mL

ST=

HbA1c:

%

ST=

Date of Graft Failure:

Pancreas Primary Cause of Graft Failure:

Specify:

Contributory causes of graft failure:

Pancreas Graft/Vascular Thrombosis:

YES NO UNK

Pancreas Infection:

YES NO UNK

Bleeding:

YES NO UNK

Anastomotic Leak:

YES NO UNK

Hyperacute Rejection:

YES NO UNK

Pancreas Acute Rejection:

YES NO UNK

Biopsy Proven Isletitis:

YES NO UNK

Pancreatitis:

YES NO UNK

Other, Specify:

Pancreas Transplant Complications:

(Not leading to graft failure.)

Pancreatitis:*

YES NO UNK

Anastomotic Leak:*

YES NO UNK

Abscess or Local Infection:*

YES NO UNK

Pancreas Transplant Complications: Other

Yes, at least one episode treated with anti-rejection agent

Yes, none treated with additional anti-rejection agent

No

Did patient have any acute rejection episodes between transplant and discharge:*

Immunosuppressive Information

Are any medications given currently for maintenance or anti-rejection:*

YES NO

Immunosuppressive Medications

View Immunosuppressive Medications

Definitions Of Immunosuppressive Medications

For each of the immunosuppressive medications listed, select **Ind** (Induction), **Maint** (Maintenance) or **AR** (Anti-rejection) to indicate all medications that were prescribed for the recipient during the initial transplant hospitalization period, and for what reason. If a medication was not given, leave the associated box(es) blank.

Induction (Ind) immunosuppression includes all medications given for a short finite period in the perioperative period for the purpose of preventing acute rejection. Though the drugs may be continued after discharge for the first 30 days after transplant, it will not be used long-term for immunosuppressive maintenance. Induction agents are usually polyclonal, monoclonal, or IL-2 receptor antibodies (example: methylprednisolone, Campath, Thymoglobulin, or Simulect). Some of these drugs might be used for another finite period for rejection therapy and would be recorded as anti-rejection therapy if used for this reason. For each induction medication indicated, write the total number of days the drug was actually administered in the space provided. For example, if Simulect was given in 2 doses a week apart then the total number of days would be 2, even if the second dose was given after the patient was discharged.

Maintenance (Maint) includes all immunosuppressive medications given before, during or after transplant with the intention to maintain them long-term (example: prednisone, cyclosporine, tacrolimus, mycophenolate mofetil, azathioprine, or Rapamune). This does not include any immunosuppressive medications given to treat rejection episodes, or for induction.

Candidate Name: DOB:

post-transplant period or during a specific follow-up period, usually up to 30 days after the diagnosis of acute rejection (example: methylprednisolone, or Thymoglobulin). When switching maintenance drugs (example: from tacrolimus to cyclosporine; or from mycophenolate mofetil to azathioprine) because of rejection, the drugs should not be listed under AR immunosuppression, but should be listed under maintenance immunosuppression.

If an immunosuppressive medication other than those listed is being administered (e.g., new monoclonal antibodies), select Ind, Maint, or AR next to Other Immunosuppressive Medication field, and enter the full name of the medication in the space provided. **Do not list non-immunosuppressive medications.**

Drug used for induction, acute rejection, or maintenance

| | Ind. | Days | ST | Maint | AR |
|---|--------------------------|----------------------|--------------------------|--------------------------|--------------------------|
| Steroids (prednisone, methylprednisolone, Solumedrol, Medrol) | <input type="checkbox"/> | <input type="text"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |

Drugs used for induction or acute rejection

| | Ind. | Days | ST | Maint | AR |
|---|--------------------------|----------------------|--------------------------|--------------------------|--------------------------|
| Atgam | <input type="checkbox"/> | <input type="text"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| Campath (alemtuzumab) | <input type="checkbox"/> | <input type="text"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| Cytosan (cyclophosphamide) | <input type="checkbox"/> | <input type="text"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| Methotrexate (Folex PFS, Mexate-AQ, Rheumatrex) | <input type="checkbox"/> | <input type="text"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| Rituxan (rituximab) | <input type="checkbox"/> | <input type="text"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| Simulect (basiliximab) | <input type="checkbox"/> | <input type="text"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| Thymoglobulin | <input type="checkbox"/> | <input type="text"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |

Drugs primarily used for maintenance

| | Ind. | Days | ST | Maint | AR |
|--|--------------------------|----------------------|--------------------------|--------------------------|--------------------------|
| Cyclosporine, select from the following: | | | | | |
| - Gengraf | <input type="checkbox"/> | <input type="text"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| - Neoral | <input type="checkbox"/> | <input type="text"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| - Sandimmune | <input type="checkbox"/> | <input type="text"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| - Generic cyclosporine | <input type="checkbox"/> | <input type="text"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| Imuran (azathioprine, AZA) | <input type="checkbox"/> | <input type="text"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| Leflunomide (LFL) | <input type="checkbox"/> | <input type="text"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| Mycophenolic acid, select from the following: | | | | | |
| - CellCept (MMF) | <input type="checkbox"/> | <input type="text"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| - Generic MMF (generic CellCept) | <input type="checkbox"/> | <input type="text"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| - Myfortic (mycophenolic acid) | <input type="checkbox"/> | <input type="text"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| - Generic Myfortic (generic mycophenolic acid) | <input type="checkbox"/> | <input type="text"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| mTOR inhibitors, select from the following: | | | | | |
| - Rapamune (sirolimus) | <input type="checkbox"/> | <input type="text"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| - Generic sirolimus | <input type="checkbox"/> | <input type="text"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| - Zortress (everolimus) | <input type="checkbox"/> | <input type="text"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| Nulojix (belatacept) | <input type="checkbox"/> | <input type="text"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| Tacrolimus, select from the following: | | | | | |
| - Astagraf XL (extended release tacrolimus) | <input type="checkbox"/> | <input type="text"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| - Envarsus XR (tacrolimus XR) | <input type="checkbox"/> | <input type="text"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| - Prograf (tacrolimus) | <input type="checkbox"/> | <input type="text"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| - Generic tacrolimus (generic Prograf) | <input type="checkbox"/> | <input type="text"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |

Other drugs

| | Ind. | Days | ST | Maint | AR |
|--|------|------|----|-------|----|
| | | | | | |

Candidate Name: DOB:

Other immunosuppressive medication, specify: